Intellia Therapeutics Management

Management criteria checks 2/4

Intellia Therapeutics' CEO is John Leonard, appointed in Jan 2018, has a tenure of 6.25 years. total yearly compensation is $10.10M, comprised of 6.2% salary and 93.8% bonuses, including company stock and options. directly owns 0.86% of the company’s shares, worth €16.12M. The average tenure of the management team and the board of directors is 5.2 years and 9 years respectively.

Key information

John Leonard

Chief executive officer

US$10.1m

Total compensation

CEO salary percentage	6.2%
CEO tenure	6.3yrs
CEO ownership	0.9%
Management average tenure	5.2yrs
Board average tenure	9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has John Leonard's remuneration changed compared to Intellia Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-US$481m
Sep 30 2023	n/a	n/a	-US$462m
Jun 30 2023	n/a	n/a	-US$453m
Mar 31 2023	n/a	n/a	-US$430m
Dec 31 2022	US$10m	US$630k	-US$474m
Sep 30 2022	n/a	n/a	-US$442m
Jun 30 2022	n/a	n/a	-US$400m
Mar 31 2022	n/a	n/a	-US$369m
Dec 31 2021	US$10m	US$600k	-US$268m
Sep 30 2021	n/a	n/a	-US$229m
Jun 30 2021	n/a	n/a	-US$185m
Mar 31 2021	n/a	n/a	-US$149m
Dec 31 2020	US$4m	US$580k	-US$134m
Sep 30 2020	n/a	n/a	-US$120m
Jun 30 2020	n/a	n/a	-US$116m
Mar 31 2020	n/a	n/a	-US$109m
Dec 31 2019	US$904k	US$559k	-US$100m
Sep 30 2019	n/a	n/a	-US$90m
Jun 30 2019	n/a	n/a	-US$89m
Mar 31 2019	n/a	n/a	-US$86m
Dec 31 2018	US$10m	US$550k	-US$85m
Sep 30 2018	n/a	n/a	-US$90m
Jun 30 2018	n/a	n/a	-US$83m
Mar 31 2018	n/a	n/a	-US$76m
Dec 31 2017	US$3m	US$396k	-US$68m

Compensation vs Market: John's total compensation ($USD10.10M) is above average for companies of similar size in the German market ($USD1.62M).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.

CEO

John Leonard (66 yo)

6.3yrs

Tenure

US$10,096,590

Compensation

Dr. John M. Leonard, M. D. is an Executive Partner at Tyree & D'Angelo Partners. He serves as Director at 3T Biosciences, Inc. since October 2022. He has been Independent Director at IQVIA Holdings Inc. si...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
John Leonard	President	6.3yrs	US$10.10m	0.86% $ 16.1m
Glenn Goddard	Executive VP	5.5yrs	US$3.43m	0.019% $ 349.8k
Laura Sepp-Lorenzino	Executive VP & Chief Scientific Officer	4.9yrs	US$3.72m	0.020% $ 375.8k
James Basta	Executive VP	2.8yrs	US$3.63m	0.018% $ 344.2k
David Lebwohl	Executive VP & Chief Medical Officer	4yrs	US$3.72m	0.030% $ 568.9k
Derek Hicks	Executive VP & Chief Business Officer	2.3yrs	US$5.08m	0.069% $ 1.3m
Nessan Bermingham	Founder & Member of Scientific Advisor Board	9.9yrs	US$11.27m	no data
Rachel Haurwitz	Co-Founder	9.9yrs	US$311.57k	no data
Andrew May	Founder and Member of Scientific Advisor Board	no data	no data	no data
Jennifer Doudna	Founder & Member of Scientific Advisor Board	no data	no data	no data
Derrick Rossi	Founder & Member of Scientific Advisor Board	no data	no data	no data
Rodolphe Barrangou	Founder & Member of Scientific Advisor Board	no data	no data	no data

5.2yrs

Average Tenure

57yo

Average Age

Experienced Management: 38I's management team is seasoned and experienced (5.2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
John Leonard	President	9.8yrs	US$10.10m	0.86% $ 16.1m
Nessan Bermingham	Founder & Member of Scientific Advisor Board	no data	US$11.27m	no data
Andrew May	Founder and Member of Scientific Advisor Board	no data	no data	no data
Jennifer Doudna	Founder & Member of Scientific Advisor Board	9yrs	no data	no data
Derrick Rossi	Founder & Member of Scientific Advisor Board	9yrs	no data	no data
Rodolphe Barrangou	Founder & Member of Scientific Advisor Board	no data	no data	no data
Luciano Marraffini	Founder & Member of Scientific Advisor Board	no data	no data	no data
Erik Sontheimer	Founder & Member of Scientific Advisor Board	no data	no data	no data
Arthur Krieg	Member of Scientific Advisory Board	no data	no data	no data
Beverly Davidson	Member of Scientific Advisory Board	9.3yrs	no data	no data
Franciscus A. G. Verwiel	Independent Chairman of the Board	6.8yrs	US$495.80k	0.0076% $ 141.5k
William Chase	Independent Director	less than a year	no data	0.0070% $ 131.9k

9.0yrs

Average Tenure

60yo

Average Age

Experienced Board: 38I's board of directors are considered experienced (9 years average tenure).

Intellia Therapeutics Management

Management criteria checks 2/4

Key information

Recent management updates

President recently sold €519k worth of stock

Intellia Therapeutics, Inc. Announces Resignation of John F. Crowley from the Board of Directors of Company and Its Committees

Insufficient new directors

Intellia Therapeutics, Inc. Appoints Eliana Clark, Phd, Executive Vice President and Chief Technical Officer

Intellia Therapeutics, Inc. Announces Resignation of Jean-François Formela as Board Member

President recently sold €234k worth of stock

Recent updates

Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 3 MAGNITUDE Study of NTLA-2001 as Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy

New minor risk - Shareholder dilution

Intellia Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $375.727167 million.

Full year 2023 earnings released: US$5.42 loss per share (vs US$6.16 loss in FY 2022)

Intellia Therapeutics, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Intellia Therapeutics, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine

President recently sold €519k worth of stock

Intellia Therapeutics, Inc. Announces Resignation of John F. Crowley from the Board of Directors of Company and Its Committees

Third quarter 2023 earnings released: US$1.38 loss per share (vs US$1.49 loss in 3Q 2022)

New minor risk - Share price stability

Intellia Therapeutics, Inc. Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 At the 4th International ATTR Amyloidosis Meeting

Insufficient new directors

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Second quarter 2023 earnings released: US$1.40 loss per share (vs US$1.33 loss in 2Q 2022)

Intellia Therapeutics, Inc. Appoints Eliana Clark, Phd, Executive Vice President and Chief Technical Officer

Intellia Therapeutics, Inc. Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)

Intellia Therapeutics, Inc. Announces Resignation of Jean-François Formela as Board Member

First quarter 2023 earnings released: US$1.18 loss per share (vs US$1.97 loss in 1Q 2022)

Full year 2022 earnings released: US$6.16 loss per share (vs US$3.78 loss in FY 2021)

President recently sold €234k worth of stock

Intellia Therapeutics Presents New Interim Data from First-In-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)

Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001

Third quarter 2022 earnings released: US$1.49 loss per share (vs US$0.97 loss in 3Q 2021)

Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 ACAAI Annual Scientific Meeting

Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)

Intellia Therapeutics, Inc. Receives U.S. FDA Orphan Drug Designation for NTLA-2002, an Investigational CRISPR Therapy for the Treatment of Hereditary Angioedema

Intellia Therapeutics, Inc. to Present Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema At the 2022 Bradykinin Symposium

Second quarter 2022 earnings released: US$1.33 loss per share (vs US$1.01 loss in 2Q 2021)

Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. Announces Additional Positive Interim Data from an Ongoing Phase 1 Study of Their Lead Investigational in Vivo Genome Editing Candidate, NTLA-2001

Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the International Liver Congress™ 2022

First quarter 2022 earnings released: US$1.97 loss per share (vs US$0.69 loss in 1Q 2021)

Intellia Therapeutics, Inc. Names Muna Bhanji to Its Board of Directors

Intellia Therapeutics, Inc., Annual General Meeting, Jun 14, 2022

Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2a Clinical Trial of NTLA-5001 for Treatment of Acute Myeloid Leukemia

Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Intellia Therapeutics, Inc. (NasdaqGM : NTLA) acquired Rewrite Therapeutics, Inc. for $200 million.

Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema

Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy

Third quarter 2021 earnings released: US$0.97 loss per share (vs US$0.47 loss in 3Q 2020)

Intellia Therapeutics, Inc. announces U.S. Food and Drug Administration accept the investigational new drug (IND) application for NTLA-5001

Second quarter 2021 earnings released: US$1.01 loss per share (vs US$0.61 loss in 2Q 2020)

Intellia Therapeutics, Inc.(NasdaqGM:NTLA) dropped from Russell 3000E Index

Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2021 Peripheral Nerve Society Annual Meeting

First quarter 2021 earnings released: US$0.69 loss per share (vs US$0.63 loss in 1Q 2020)

Intellia Therapeutics, Inc. Announces the Presentation of New Data from Its CRISPR/Cas9 Platform

Intellia Therapeutics Presents Preclinical Proof of Concept for CRISPR-based In Vivo Editing of Bone Marrow at Keystone eSymposium

New 90-day low: €37.50

Full year 2020 earnings released: US$2.40 loss per share (vs US$2.11 loss in FY 2019)

Revenue misses expectations

New 90-day high: €60.00

Intellia Therapeutics, Inc. Achieves Normal Human Alpha-1 Antitrypsin Protein Levels in Non-Human Primates Through Targeted Gene Insertion for the Treatment of AAT Deficiency

New 90-day high: €41.59

Intellia Therapeutics Receives Grant to Develop Curative CRISPR/Cas9 in Vivo Sickle Cell Disease Treatments

Intellia Therapeutics Doses First Patient in Landmark CRISPR/Cas9 Clinical Trial of NTLA-2001 for the Treatment of Transthyretin Amyloidosis

Revenue beats expectations

Third quarter 2020 earnings released: US$0.47 loss per share

New 90-day high: €22.96

Intellia Therapeutics, Inc. Receives Authorization to Initiate Phase 1 Clinical Trial of NTLA-2001 for Transthyretin Amyloidosis (ATTR)

New 90-day high: €20.96

Intellia Therapeutics, Inc. Announces Board Changes

Intellia Therapeutics, Inc. Presents New Preclinical Data Showing Persistent in Vivo Editing and Durability of Effect Following CRISPR/Cas9-Based Treatment

Intellia Therapeutics, Inc.(NasdaqGM:NTLA) dropped from Russell Microcap Value Index

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team